Check out the latest news from Cinclus Pharma
Christer Ahlberg, CEO of Cinclus Pharma, was invited to present the company's latest updates and the development of linaprazan glurate at the Redeye Investor Forum in Gothenburg on April 18, 2024.
Read more
Cinclus Pharma's CEO, Christer Ahlberg, presented Cinclus Pharma at the ABGCS seminar on November 22-23.
Read more
Cinclus Pharma today announces that the company has completed a successful so-called end-of-phase-II meeting, with the US Food and Drug Administration (FDA) for the indication erosive gastroesophageal reflux disease (eGERD). The FDA broadly accepted Cinclus Pharma's proposal for the phase III program, including study design and primary endpoint for the studies. The positive outcome allows Cinclus Pharma to proceed with its phase III program.
Read more